A 32-year-old man from Delhi presents with a 10-day history of sustained fever, headache, and abdominal pain. Blood culture grows Salmonella typhi sensitive to fluoroquinolones, third-generation cephalosporins, and azithromycin, but resistant to chloramphenicol and trimethoprim-sulfamethoxazole. What is the drug of choice for treatment of this enteric fever?

Explanation

## Drug of Choice for Enteric Fever (Susceptible Strains) ### Current Treatment Landscape **Key Point:** In India and most endemic regions, the epidemiology of S. typhi resistance has evolved significantly. Multidrug-resistant (MDR) strains (resistant to chloramphenicol, trimethoprim-sulfamethoxazole, and ampicillin) emerged in the 1980s–1990s and are now widespread. Fluoroquinolone-susceptible strains remain common in many regions, making fluoroquinolones the preferred first-line agent for uncomplicated enteric fever in susceptible cases. ### Fluoroquinolones (Ciprofloxacin / Ofloxacin) - **Mechanism:** Inhibit bacterial DNA gyrase; achieve excellent intracellular and tissue penetration. - **Dosing:** Ciprofloxacin 500 mg twice daily for 5–7 days (uncomplicated) or 7–14 days (complicated). - **Advantages:** Oral bioavailability, rapid defervescence (typically 3–5 days), low relapse rates (~5%), cost-effective. - **Efficacy:** >95% cure rate in susceptible strains. ### Why Other Options Are Suboptimal Here | Drug | Status | Reason | |------|--------|--------| | **Chloramphenicol** | Obsolete | Organism is **resistant** (per culture); high relapse rates (15–20%); bone marrow toxicity; poor intracellular penetration. | | **TMP-SMX** | Obsolete | Organism is **resistant**; was first-line before MDR emergence (1980s). | | **Ceftriaxone** | Alternative | Effective (especially for severe/complicated cases, pregnancy, children <5 years); requires IV/IM dosing; higher cost; reserved for severe disease or when fluoroquinolones contraindicated. | ### Clinical Pearl **High-Yield:** In a patient with **susceptible** S. typhi (no fluoroquinolone resistance), ciprofloxacin or ofloxacin is the preferred first-line agent in India and South Asia. Ceftriaxone is reserved for severe/complicated cases, meningitis, or pregnancy. ### Regional Variation - **Fluoroquinolone-resistant S. typhi (FQRT):** Emerging in parts of South Asia; in these cases, ceftriaxone or azithromycin becomes first-line. - **Extensively drug-resistant (XDR) S. typhi:** Requires carbapenems or newer agents; rare but reported in Pakistan and India. **Mnemonic:** **FQRT** = Fluoroquinolone-Resistant Typhi (when this emerges, switch to **3GC** = third-generation cephalosporins). ### Recommended Regimen for This Case - **Ciprofloxacin 500 mg PO twice daily for 7 days** (uncomplicated enteric fever, susceptible strain). - Monitor for defervescence; most patients become afebrile by day 3–5. - Advise adequate hydration and nutritional support.